The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | B | Blood and blood forming organs | |
2 | B02 | Antihemorrhagics | |
3 | B02B | Vitamin K and other hemostatics | |
4 | B02BX | Other systemic hemostatics | |
5 | B02BX09 |
Active Ingredient | Description | |
---|---|---|
Fostamatinib |
Fostamatinib is a tyrosine kinase inhibitor with demonstrated activity against spleen tyrosine kinase (SYK), through its major metabolite R406. R406 reduces antibody-mediated destruction of platelets. Fostamatinib is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients. |
Title | Information Source | Document Type | |
---|---|---|---|
TAVALISSE Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
TAVLESSE Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.